Dual inhibitory effect of bredinin - PubMed

Dual inhibitory effect of bredinin

T Kusumi et al. Cell Biochem Funct. 1989 Jul.

Abstract

Bredinin inhibition of cell growth was investigated in the mouse lymphoma cell line L5178Y. Bredinin caused the accumulation of IMP and the reduction of XMP. It was converted to the 5'-phosphate within the cells. Bredinin 5'-phosphate but not bredinin competitively inhibited both IMP dehydrogenase and GMP synthetase. Thus the inhibition of cell growth is probably due to bredinin 5'-phosphate, which inhibits the consecutive enzyme reactions IMP dehydrogenase and GMP synthetase. These inhibitions result in the accumulation of IMP and the reduction of XMP.

Similar articles

• Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells.

  Sakaguchi K, Tsujino M, Hayashi M, Kawai K, Mizuno K, Hayano K. Sakaguchi K, et al. J Antibiot (Tokyo). 1976 Dec;29(12):1320-7. doi: 10.7164/antibiotics.29.1320. J Antibiot (Tokyo). 1976. PMID: 188795

• Action of bredinin on mammalian cells.

  Sakaguchi K, Tsujino M, Yoshizawa M, Mizuno K, Hayano K. Sakaguchi K, et al. Cancer Res. 1975 Jul;35(7):1643-8. Cancer Res. 1975. PMID: 1055633

• Effect of bredinin and its aglycone on L5178Y cells.

  Sakaguchi K, Tsujino M, Mizuno K, Hayano K, Ishida N. Sakaguchi K, et al. J Antibiot (Tokyo). 1975 Oct;28(10):798-803. doi: 10.7164/antibiotics.28.798. J Antibiot (Tokyo). 1975. PMID: 171246

• Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells.

  Koyama H, Tsuji M. Koyama H, et al. Biochem Pharmacol. 1983 Dec 1;32(23):3547-53. doi: 10.1016/0006-2952(83)90301-5. Biochem Pharmacol. 1983. PMID: 6140013

• Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells.

  Dix DE, Lehman CP, Jakubowski A, Moyer JD, Handschumacher RE. Dix DE, et al. Cancer Res. 1979 Nov;39(11):4485-90. Cancer Res. 1979. PMID: 498080 No abstract available.

Cited by

• Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis.

  Nagai K. Nagai K. Medicina (Kaunas). 2023 Mar 17;59(3):601. doi: 10.3390/medicina59030601. Medicina (Kaunas). 2023. PMID: 36984602 Free PMC article. Review.

• Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.

  Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M; Japanese Pediatric IgA Nephropathy Treatment Study Group. Yoshikawa N, et al. Pediatr Nephrol. 2008 May;23(5):757-63. doi: 10.1007/s00467-007-0731-8. Epub 2008 Jan 26. Pediatr Nephrol. 2008. PMID: 18224343 Clinical Trial.

• Advancing Cancer Treatment by Targeting Glutamine Metabolism-A Roadmap.

  Halama A, Suhre K. Halama A, et al. Cancers (Basel). 2022 Jan 22;14(3):553. doi: 10.3390/cancers14030553. Cancers (Basel). 2022. PMID: 35158820 Free PMC article. Review.

• Mizoribine: a new approach in the treatment of renal disease.

  Kawasaki Y. Kawasaki Y. Clin Dev Immunol. 2009;2009:681482. doi: 10.1155/2009/681482. Epub 2009 Dec 13. Clin Dev Immunol. 2009. PMID: 20052390 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley